HMNC Brain Health Expands International Patent Portfolio with Two Stress-axis Related Substances for Major Depressive Disorder
In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects
HMNC Brain Health Names Nir Naor New Chief Financial Officer
Munich, December 14, 2021 - HMNC Brain Health (...) announced today the appointment of Nir Naor as its new Chief Financial Officer, effective immediately. Mr. Naor succeeds Rainer Sturm, who will remain with the Company to help ensure a smooth transition.
Personalised Medicine for Psychiatry Requires Novel Trial Designs
An inspiring article in the latest Issue of International Clinical Trials: Our Chief Clinical Development Officer, Dr. Hans Eriksson shares his expertise about the requirements of novel trial designs in personalized medicine for psychiatry.
“This article is taken from International Clinical Trials November 2021, pages 18-20. © Samedan Ltd”
The whole article can be viewed here (pp. 18-20)